<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d1 20130915//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Genes (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Genes (Basel)</journal-id><journal-id journal-id-type="publisher-id">genes</journal-id><journal-title-group><journal-title>Genes</journal-title></journal-title-group><issn pub-type="epub">2073-4425</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4276928</article-id><article-id pub-id-type="pmid">25513882</article-id><article-id pub-id-type="doi">10.3390/genes5041095</article-id><article-id pub-id-type="publisher-id">genes-05-01095</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Altered Actions of Memantine and NMDA-Induced Currents in a New Grid2-Deleted Mouse Line </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kumagai</surname><given-names>Ayako</given-names></name><xref ref-type="aff" rid="af1-genes-05-01095">1</xref><xref ref-type="author-notes" rid="fn1-genes-05-01095">†</xref></contrib><contrib contrib-type="author"><name><surname>Fujita</surname><given-names>Akira</given-names></name><xref ref-type="aff" rid="af2-genes-05-01095">2</xref><xref ref-type="author-notes" rid="fn1-genes-05-01095">†</xref></contrib><contrib contrib-type="author"><name><surname>Yokoyama</surname><given-names>Tomoki</given-names></name><xref ref-type="aff" rid="af2-genes-05-01095">2</xref><xref ref-type="author-notes" rid="fn1-genes-05-01095">†</xref></contrib><contrib contrib-type="author"><name><surname>Nonobe</surname><given-names>Yuki</given-names></name><xref ref-type="aff" rid="af2-genes-05-01095">2</xref><xref ref-type="author-notes" rid="fn1-genes-05-01095">†</xref></contrib><contrib contrib-type="author"><name><surname>Hasaba</surname><given-names>Yasuhiro</given-names></name><xref ref-type="aff" rid="af2-genes-05-01095">2</xref><xref ref-type="author-notes" rid="fn1-genes-05-01095">†</xref></contrib><contrib contrib-type="author"><name><surname>Sasaki</surname><given-names>Tsutomu</given-names></name><xref ref-type="aff" rid="af3-genes-05-01095">3</xref></contrib><contrib contrib-type="author"><name><surname>Itoh</surname><given-names>Yumi</given-names></name><xref ref-type="aff" rid="af1-genes-05-01095">1</xref></contrib><contrib contrib-type="author"><name><surname>Koura</surname><given-names>Minako</given-names></name><xref ref-type="aff" rid="af4-genes-05-01095">4</xref></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Osamu</given-names></name><xref ref-type="aff" rid="af4-genes-05-01095">4</xref></contrib><contrib contrib-type="author"><name><surname>Adachi</surname><given-names>Shigeki</given-names></name><xref ref-type="aff" rid="af5-genes-05-01095">5</xref></contrib><contrib contrib-type="author"><name><surname>Ryo</surname><given-names>Haruko</given-names></name><xref ref-type="aff" rid="af5-genes-05-01095">5</xref></contrib><contrib contrib-type="author"><name><surname>Kohara</surname><given-names>Arihiro</given-names></name><xref ref-type="aff" rid="af6-genes-05-01095">6</xref></contrib><contrib contrib-type="author"><name><surname>Tripathi</surname><given-names>Lokesh P.</given-names></name><xref ref-type="aff" rid="af7-genes-05-01095">7</xref></contrib><contrib contrib-type="author"><name><surname>Sanosaka</surname><given-names>Masato</given-names></name><xref ref-type="aff" rid="af1-genes-05-01095">1</xref></contrib><contrib contrib-type="author"><name><surname>Fukushima</surname><given-names>Toshiki</given-names></name><xref ref-type="aff" rid="af2-genes-05-01095">2</xref></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Hiroyuki</given-names></name><xref ref-type="aff" rid="af2-genes-05-01095">2</xref></contrib><contrib contrib-type="author"><name><surname>Kitagawa</surname><given-names>Kazuo</given-names></name><xref ref-type="aff" rid="af3-genes-05-01095">3</xref></contrib><contrib contrib-type="author"><name><surname>Nagaoka</surname><given-names>Yasuo</given-names></name><xref ref-type="aff" rid="af8-genes-05-01095">8</xref></contrib><contrib contrib-type="author"><name><surname>Kawahara</surname><given-names>Hidehisa</given-names></name><xref ref-type="aff" rid="af8-genes-05-01095">8</xref></contrib><contrib contrib-type="author"><name><surname>Mizuguchi</surname><given-names>Kenji</given-names></name><xref ref-type="aff" rid="af7-genes-05-01095">7</xref></contrib><contrib contrib-type="author"><name><surname>Nomura</surname><given-names>Taisei</given-names></name><xref ref-type="aff" rid="af5-genes-05-01095">5</xref></contrib><contrib contrib-type="author"><name><surname>Matsuda</surname><given-names>Junichiro</given-names></name><xref ref-type="aff" rid="af4-genes-05-01095">4</xref></contrib><contrib contrib-type="author"><name><surname>Tabata</surname><given-names>Toshihide</given-names></name><xref ref-type="aff" rid="af2-genes-05-01095">2</xref><xref rid="c1-genes-05-01095" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Takemori</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="af1-genes-05-01095">1</xref><xref rid="c1-genes-05-01095" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-genes-05-01095"><label>1</label>Laboratory of Cell Signaling and Metabolic Disease, National Institute of Biomedical Innovation, Saito-Asagi, Ibaraki, Osaka 567-0085, Japan; E-Mails: <email>a-kumagai@nibio.go.jp</email> (A.K.); <email>y-itou@nibio.go.jp</email> (Y.I.); <email>m-sanosaka@nibio.go.jp</email> (M.S.)</aff><aff id="af2-genes-05-01095"><label>2</label>Laboratory for Neural Information Technology, Graduate School of Science and Engineering, University of Toyama, Toyama 930-8555, Japan; E-Mails: <email>fujita0153@gmail.com</email> (A.F.); <email>m1371119@ems.u-toyama.ac.jp</email> (T.Y.); <email>weather4519@gmail.com</email> (Y.N.); <email>takegoshiyoshihiro45@gmail.com</email> (Y.H.); <email>fookun3@gmail.com</email> (T.F.); <email>m1471114@ems.u-toyama.ac.jp</email> (H.T.)</aff><aff id="af3-genes-05-01095"><label>3</label>Department of Neurology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; E-Mails: <email>sasaki@medone.med.osaka-u.ac.jp</email> (T.S.); <email>kitagawa@neurol.med.osaka-u.ac.jp</email> (K.K.)</aff><aff id="af4-genes-05-01095"><label>4</label>Laboratory of Animal Models for Human Diseases, National Institute of Biomedical Innovation, Saito-Asagi, Ibaraki, Osaka 567-0085, Japan; E-Mails: <email>koura@nibio.go.jp</email> (M.K.); <email>osuzuki@nibio.go.jp</email> (O.S.); <email>jmatsuda@nibio.go.jp</email> (J.M.)</aff><aff id="af5-genes-05-01095"><label>5</label>Nomura Project, National Institute of Biomedical Innovation, Saito-Asagi, Ibaraki, Osaka 567-0085, Japan; E-Mails: <email>sadachi@nibio.go.jp</email> (S.A.); <email>hryo@nibio.go.jp</email> (H.R.); <email>n5nomura@nibio.go.jp</email> (T.N.)</aff><aff id="af6-genes-05-01095"><label>6</label>Laboratory of Cell Cultures, National Institute of Biomedical Innovation, Saito-Asagi, Ibaraki, Osaka 567-0085, Japan; E-Mail: <email>kohara@nibio.go.jp</email></aff><aff id="af7-genes-05-01095"><label>7</label>Laboratory of Bioinformatics, National Institute of Biomedical Innovation, Saito-Asagi, Ibaraki, Osaka 567-0085, Japan; E-Mails: <email>lokesh@nibio.go.jp</email> (L.P.T.); <email>kenji@nibio.go.jp</email> (K.M.)</aff><aff id="af8-genes-05-01095"><label>8</label>Department of Life Science and Biotechnology, Kansai University, Suita, Osaka 564-8680, Japan; E-Mails: <email>t010034@kansai-u.ac.jp</email> (Y.N.); <email>t912436@kansai-u.ac.jp</email> (H.K.)</aff><author-notes><fn id="fn1-genes-05-01095"><label>†</label><p><text><SENT sid="1" pm="."><plain>These authors contributed equally to this work. </plain></SENT>
</text></p></fn><corresp id="c1-genes-05-01095"><label>*</label>Authors to whom correspondence should be addressed; E-Mails: <email>takemori@nibio.go.jp</email> (H.T.); <email>ttabata@eng.u-toyama.ac.jp</email> (T.T.); Tel.: +81-72-641-9834 (H.T.); Fax: +81-72-641-9836 (H.T.); Tel.: +81-76-445-6742 (T.T.); Fax: +81-76-445-6703 (T.T.).</corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2014</year></pub-date><volume>5</volume><issue>4</issue><fpage>1095</fpage><lpage>1114</lpage><history><date date-type="received"><day>14</day><month>10</month><year>2014</year></date><date date-type="rev-recd"><day>12</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>02</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2014</copyright-year><license><license-p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Memantine is a non-competitive antagonist of the N-methyl-d-aspartate (NMDA) receptor, and is an approved drug for the treatment of moderate-to-severe Alzheimer’s disease. </plain></SENT>
<SENT sid="3" pm="."><plain>We identified a mouse strain with a naturally occurring mutation and an ataxic phenotype that presents with severe leg cramps. </plain></SENT>
<SENT sid="4" pm="."><plain>To investigate the phenotypes of these mutant mice, we screened several phenotype-modulating drugs and found that memantine (10 mg/kg) disrupted the sense of balance in the mutants. </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, the mutant mice showed an attenuated optokinetic response (OKR) and impaired OKR learning, which was also observed in wild-type mice treated with memantine. </plain></SENT>
<SENT sid="6" pm="."><plain>Microsatellite analyses indicated that the Grid2 gene-deletion is responsible for these phenotypes. </plain></SENT>
<SENT sid="7" pm="."><plain>Patch-clamp analysis showed a relatively small change in NMDA-dependent current in cultured granule cells from Grid2 gene-deleted mice, suggesting that GRID2 is important for correct NMDA receptor function. </plain></SENT>
<SENT sid="8" pm="."><plain>In general, NMDA receptors are activated after the activation of non-NMDA receptors, such as AMPA receptors, and AMPA receptor dysregulation also occurs in Grid2 mutant mice. </plain></SENT>
<SENT sid="9" pm="."><plain>Indeed, the AMPA treatment enhanced memantine susceptibility in wild-type mice, which was indicated by balance sense and OKR impairments. </plain></SENT>
<SENT sid="10" pm="."><plain>The present study explores a new role for GRID2 and highlights the adverse effects of memantine in different genetic backgrounds. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>GRID2</kwd><kwd>GluRδ2</kwd><kwd>memantine</kwd><kwd>NMDA receptor</kwd><kwd>cerebellum</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="11" pm="."><plain>1. </plain></SENT>
<SENT sid="12" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="13" pm="."><plain>Memantine (3,5-dimethyl-1-adamantanamine) is an approved drug in the treatment of moderate-to-severe Alzheimer’s disease (AD). </plain></SENT>
<SENT sid="14" pm="."><plain>Ca2+-mediated excitotoxicity in neurons is one proposed mechanism of AD, and the N-methyl-d-aspartate (NMDA) receptor is one of the major receptor channels responsible for glutamate-induced Ca2+ influx. </plain></SENT>
<SENT sid="15" pm="."><plain>Memantine binds and non-competitively inhibits NMDA receptors, which subsequently protects neurons from glutamate-induced excitotoxicity [1,2]. </plain></SENT>
</text></p><p><text><SENT sid="16" pm="."><plain>Glutamate is essential for excitatory synaptic transmission mediated by ionotropic glutamate receptors, which include NMDA receptors and non-NMDA receptors, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors [3]. </plain></SENT>
<SENT sid="17" pm="."><plain>NMDA receptor activation is dependent on the membrane potential that is evoked by non-NMDA receptor function [4]. </plain></SENT>
<SENT sid="18" pm="."><plain>Under pathological conditions, the voltage-dependent regulation of NMDA receptors is believed to be impaired, and memantine is thought to alleviate excitotoxicity by the unregulated NMDA receptor. </plain></SENT>
</text></p><p><text><SENT sid="19" pm="."><plain>Unlike memantine, other NMDA receptor antagonists, such as MK-801 [5], are considered neurotoxins because they inhibit normal excitotoxic neurotransmission as well as pathological physiological neurotransmission. </plain></SENT>
<SENT sid="20" pm="."><plain>Although memantine is considered a relatively safe drug, some adverse effects, such as dizziness [6], have been reported. </plain></SENT>
<SENT sid="21" pm="."><plain>Such adverse effects are likely to result from individual differences among patients, especially in their genetic backgrounds. </plain></SENT>
<SENT sid="22" pm="."><plain>However, the causes of adverse effects to memantine have not yet been clarified. </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>The glutamate receptor ionotropic delta 2 (GRID2, also known as GluRδ2) is abundantly expressed in cerebellar Purkinje cells, and shares sequence homology with other glutamate receptors. </plain></SENT>
<SENT sid="24" pm="."><plain>Despite its name and these homologies, GRID2 does not bind glutamate or other glutamate analogs [7,8,9]. </plain></SENT>
<SENT sid="25" pm="."><plain>Mice with an impaired Grid2 gene exhibit a broad range of phenotypes, such as cerebellar ataxia, poor motor learning, and memory dysfunction. </plain></SENT>
<SENT sid="26" pm="."><plain>In addition to the known phenotypes in mice, new phenotypes presumably involving NMDA receptor dysfunction or memantine effects, such as nystagmus (in frogs) [10], oculomotor apraxia (in cats) [11,12], dementia (in humans) [13,14], have been observed in human patients with GRID2 gene deletions [15,16,17,18]. </plain></SENT>
<SENT sid="27" pm="."><plain>However, there is not sufficient evidence to ascribe these complex symptoms in human patients to GRID2 gene deletions. </plain></SENT>
</text></p><p><text><SENT sid="28" pm="."><plain>Here, we report a new deletion in the mouse Grid2 gene that is accompanied by ataxia. </plain></SENT>
<SENT sid="29" pm="."><plain>Administration of memantine led to impaired balance in ataxic mice, and the mutant mice showed deficits in the optokinetic response (OKR) and its learning. </plain></SENT>
<SENT sid="30" pm="."><plain>These optokinetic impairments were also sensitive to memantine. </plain></SENT>
<SENT sid="31" pm="."><plain>In addition, only a small population of cultured granule cells isolated from the mutant mice showed memantine-sensitive NMDA-induced currents. </plain></SENT>
<SENT sid="32" pm="."><plain>These phenomena were mimicked in wild-type (WT) mice following co-treatment with memantine and AMPA. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec><title><text><SENT sid="33" pm="."><plain>2. </plain></SENT>
<SENT sid="34" pm="."><plain>Results </plain></SENT>
</text></title><sec><title><text><SENT sid="35" pm="."><plain>2.1. </plain></SENT>
<SENT sid="36" pm="."><plain>The Hereditary Ataxic Mouse is Sensitive to Memantine </plain></SENT>
</text></title><p><text><SENT sid="37" pm="."><plain>Two ataxic (male and female) mice appeared spontaneously in the same litter from a mating pair of hetero mice with the knockout (KO) allele for Salt-Inducible Kinase 3 (Sik3: Sik3tm1Htake/+) [19] on a C57BL/6J (B6) genetic background. </plain></SENT>
<SENT sid="38" pm="."><plain>The male was Sik3+/−, but the female was Sik3+/+. </plain></SENT>
<SENT sid="39" pm="."><plain>Because these ataxic mice failed to produce offspring by natural mating, we performed in vitro fertilization (IVF) using these ataxic mice and confirmed the heredity of the phenotype. </plain></SENT>
<SENT sid="40" pm="."><plain>To expound the mouse population, the original sperm of the ataxic male was also used for other IVF with the oocyte of normal B6 female, and offspring with the ataxic phenotype were obtained at the F2 generation (numbers of normal male, ataxic male, normal female, and ataxic female were 4, 1, 9, and 2, respectively), suggesting a recessively-inherited phenotype. </plain></SENT>
<SENT sid="41" pm="."><plain>Despite showing normal forelimb movements, the mutant offspring were characterized by a short-stepped gait and frequent falls due to suspected leg cramps (Figure 1A). </plain></SENT>
</text></p><p><text><SENT sid="42" pm="."><plain>To examine whether the phenotype was caused by a neurogenic disorder, neuropharmacological compounds were tested in the normal and mutant mice. </plain></SENT>
<SENT sid="43" pm="."><plain>Because anesthesia (1% isoflurane) [20] alleviated leg cramps in the mutant mice, we first selected anticonvulsant drugs including gamma-aminobutyric acid (GABA) receptor activators and NMDA receptor antagonists (Table 1). </plain></SENT>
<SENT sid="44" pm="."><plain>The GABA-A receptor activators felbamate and nitrazepam failed to modulate the phenotypes in the mutant mice. </plain></SENT>
<SENT sid="45" pm="."><plain>Whereas, memantine (10 mg/kg), an NMDA and 5HT3 receptor antagonist which is also reported to exert agonistic actions for the dopamine D2 receptor [21,22], impaired balance in the mutant mice, but not normal mice (Figure 1B and Supplementary Movie 1). </plain></SENT>
<SENT sid="46" pm="."><plain>Movement traces of the mice (Figure 1C) confirmed that 10 mg/kg memantine had no significant effect on walking in normal mice. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="genes-05-01095-f001" position="float"><label>Figure 1</label><caption><p><text><SENT sid="47" pm="."><plain>Isolation of ataxic mice with memantine susceptibility. </plain></SENT>
<SENT sid="48" pm="."><plain>(A) A mouse (6-month-old female) that exhibited an ataxic phenotype with rigid hind limbs. </plain></SENT>
<SENT sid="49" pm="."><plain>The phenotype became more severe with age; (B) Footprint analyses 10 min after memantine treatment (10 mg/kg, 12-week-old male). </plain></SENT>
<SENT sid="50" pm="."><plain>The soles of the hind limbs were labeled with India ink for a mouse that walked freely on paper. </plain></SENT>
<SENT sid="51" pm="."><plain>Rollover by the mutant mouse after memantine treatment is shown (lower right); (C) Monitoring mice walking after memantine treatment (10 mg/kg, 12-week-old male). </plain></SENT>
<SENT sid="52" pm="."><plain>The position of the mouse’s head was tracked (left), and the walking distance was recorded for 5 min (right; expressed as the mean and SD; n = 6). * p &lt; 0.05, ** p &lt; 0.01. </plain></SENT>
</text></p></caption><graphic xlink:href="genes-05-01095-g001"/></fig></SecTag><p><text><SENT sid="53" pm="."><plain>Next, we tested other NMDA receptor modulators. </plain></SENT>
<SENT sid="54" pm="."><plain>Similar to memantine, the NMDA receptor antagonist MK-801 (10 mg/kg) led to balance disturbances in the mutant mice. </plain></SENT>
<SENT sid="55" pm="."><plain>However, the normal mice also showed balance disturbances at this dose (Table 1). </plain></SENT>
<SENT sid="56" pm="."><plain>(R)-CPP also produced balance disturbances only in the mutant mice (Supplementary Movie 2), whereas ifenprodil, Ro25-6981, or the AMPA receptor antagonist DNQX did not produce balance disturbances in the mutant or normal mice. </plain></SENT>
<SENT sid="57" pm="."><plain>However, slower movements were observed in mutant mice following administration of DL-AP7. </plain></SENT>
</text></p><p><text><SENT sid="58" pm="."><plain>Because serotonin reuptake inhibitors are used to treat vertigo [23], and the 5HT3 antagonist ondansetron causes headache and dizziness [24], we examined whether ondansetron affected the mutant mice. </plain></SENT>
<SENT sid="59" pm="."><plain>Both mutant and normal mice showed decreased activity with ondansetron (10 mg/kg; Supplementary Movie 3), but no effect that was specific to mutant mice was observed. </plain></SENT>
<SENT sid="60" pm="."><plain>Moreover, enhanced cholinergic signaling following donepezil treatment [21] and activation of dopamine signals by L-Dopa [21,22] had no significant effect on behavior in both normal and mutant mice (Table 1). </plain></SENT>
<SENT sid="61" pm="."><plain>These results suggest that, in addition to the ataxic phenotype, the mutant mice were characterized by enhanced memantine susceptibility, which was probably due to impaired NMDA receptor functions. </plain></SENT>
<SENT sid="62" pm="."><plain>The inconsistency in the efficacy of NMDA receptor antagonists on balance disturbance might result from differences in NMDA receptor subunit subtype-specificity and/or effective dose among the antagonists; 10 mg/kg and 10–20 mg/kg might be the threshold doses to affect balance in the mutant mice for memantine and (R)-CPP, respectively. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="genes-05-01095-t001" position="float"><object-id pub-id-type="pii">genes-05-01095-t001_Table 1</object-id><label>Table 1</label><caption><p><text><SENT sid="63" pm="."><plain>Pharmacological effectors on mutant mice phenotypes. </plain></SENT>
</text></p></caption><table frame="hsides" rules="rows"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>Chemical </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>Category </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>Dose(mg/kg) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>Number of Mice </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>Movement of Normal Mice </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>Movement of Mutant Mice </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>Memantine </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>NMDA-R antagonist </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>210 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>22 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>NSNS </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>NSBalance loss </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>MK-801 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>NMDA-R antagonist </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>210 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>23 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>NSBalance loss </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>NSBalance loss </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>DL-AP7 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>NMDA-R antagonist </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>30 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>NS </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>Slow movement </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>(R)-CPP </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>NMDA-R antagonist(NR2A antagonist) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>1020 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>42 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>NSNS </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>Balance loss *Balance loss </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>Ro25-6981 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>NMDA-R antagonist </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>210 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>33 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>NSNS </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>NSNS </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>Ifenprodil </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>NMDA-R antagonist(NR2B antagonist) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>210 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>33 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>NSNS </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>NSNS </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>Felbamate </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>NR2B antagonistGABA-R activator </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>30 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>NS </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>NS </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>Nitrazepam </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>GABA-R activator </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>30 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>NS </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>NS </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>Isoflurane </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>GABA-R activator </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>1% in air </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>Slip </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>Slip </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>DNQX </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>AMPA/Kainatereceptor antagonist </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>210 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>33 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>NSNS </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>NSNS </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>Ondansetron </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>5-HT3 antagonist </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>510 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>22 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>NSNot move </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>NSNot move </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>Donepezil </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>acetylcholinesteraseinhibitor </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>10 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>NS </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>NS </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>l-Dopa </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>Dopamine precursor </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>20 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>NS </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>NS </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="148" pm="."><plain>NS: No significant effect was observed. *: 2 mice. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec><title><text><SENT sid="149" pm="."><plain>2.2. </plain></SENT>
<SENT sid="150" pm="."><plain>Impaired OKR and Learning in the Ataxic Mice </plain></SENT>
</text></title><p><text><SENT sid="151" pm="."><plain>Gait disorders are a common pathology in patients with spinocerebellar degeneration, and are sometimes accompanied by vertigo resulting from oculomotor dysfunction [25,26]. </plain></SENT>
<SENT sid="152" pm="."><plain>Memantine also affects oculomotor functions in patients with cerebellar ataxia [27]. </plain></SENT>
<SENT sid="153" pm="."><plain>To examine whether our mutant mice also had oculomotor impairments, we measured the OKR and OKR adaptation, a form of cerebellum-dependent learning [28,29], and used the results from these assays to quantify memantine susceptibility (Supplementary Figure S1). </plain></SENT>
</text></p><p><text><SENT sid="154" pm="."><plain>Normal and mutant mice were subjected to the OKR assay and horizontal visual pattern oscillations were given (Figure 2A). </plain></SENT>
<SENT sid="155" pm="."><plain>The normal mice could track the stimulus screen, whereas the mutant mice could not. </plain></SENT>
<SENT sid="156" pm="."><plain>Memantine (10 mg/kg) significantly lowered the overall OKR gain throughout a 1 h session in normal mice while the OKR in mutant mice was completely abolished (Figure 2B). </plain></SENT>
</text></p><p><text><SENT sid="157" pm="."><plain>To evaluate OKR adaptation, the mean OKR gain was plotted for each 10-min interval (Figure 2C). </plain></SENT>
<SENT sid="158" pm="."><plain>Saline-injected normal mice (control) exhibited a time-dependent increase in the OKR gain, but no gain increase was observed in the mutant or the memantine-treated normal mice. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="genes-05-01095-f002" position="float"><label>Figure 2</label><caption><p><text><SENT sid="159" pm="."><plain>The optokinetic response (OKR) and its susceptibility to memantine. </plain></SENT>
<SENT sid="160" pm="."><plain>(A) The OKR of normal and mutant mice after intraperitoneal injection of saline (control) or memantine-containing saline (10 mg/kg). </plain></SENT>
<SENT sid="161" pm="."><plain>Measurements commenced 10 min after injection. </plain></SENT>
<SENT sid="162" pm="."><plain>Representative OKRs from normal and mutant mice are shown. </plain></SENT>
<SENT sid="163" pm="."><plain>The relative pupil azimuth is plotted against time. </plain></SENT>
<SENT sid="164" pm="."><plain>Each trace indicates the average over each 10-min period of a 1-h measurement session. </plain></SENT>
<SENT sid="165" pm="."><plain>Screen, movement of the stimulus screen; (B) Overall OKR gain throughout the 1-h session with or without memantine. </plain></SENT>
<SENT sid="166" pm="."><plain>Dots and error bars, mean ± SD; n = 5 for each data point. * p &lt; 0.05, ** p &lt; 0.01, and **** p &lt; 0.0001, multivariate ANOVA. </plain></SENT>
<SENT sid="167" pm="."><plain>The overall OKR gain was calculated by averaging the OKR gains for all 10-min periods in a single 1-h session (see panel C); (C) Time course of the mean OKR gain for normal (n = 5) and mutant (n = 5) mice. </plain></SENT>
<SENT sid="168" pm="."><plain>Each dot indicates the average over a 10-min period of a 1-h measurement session. </plain></SENT>
<SENT sid="169" pm="."><plain>Error bars indicate ±SD. **** p &lt; 0.0001 vs. the control for time × drug interaction, repeated measures ANOVA. </plain></SENT>
</text></p></caption><graphic xlink:href="genes-05-01095-g002"/></fig></SecTag></sec><sec><title><text><SENT sid="170" pm="."><plain>2.3. </plain></SENT>
<SENT sid="171" pm="."><plain>Microsatellite Analysis in the Ataxic Mice </plain></SENT>
</text></title><p><text><SENT sid="172" pm="."><plain>Because the pharmacological analyses were unable to predict the gene responsible for the ataxic phenotype, we performed a microsatellite analysis to identify the gene. </plain></SENT>
<SENT sid="173" pm="."><plain>Sperm were isolated from an ataxic mouse (N0: C57BL/6J[B6], B6/B6) and used to perform IVF with oocytes from C3H/HeN (C3) mice (normal: C3/C3). </plain></SENT>
<SENT sid="174" pm="."><plain>Oocytes were prepared from the N1 female (B6/C3 hetero-mice) and used for a second round of IVF using the original sperm from the N0 (B6/B6) ataxic mice, which produced 137 N2 mice (75 non-ataxic (the responsible genomic-region should be B6/C3) and 62 ataxic (the responsible genomic-region should be B6/B6)). </plain></SENT>
<SENT sid="175" pm="."><plain>Using 60 microsatellite markers and DNA from eight N2 non-ataxic mice, we screened heterogenic-regions composed of both B6 and C3 chromosomes. </plain></SENT>
<SENT sid="176" pm="."><plain>We observed that D6Mit149 (Chromosome 6, 48.93 cM) was amplified as the heterogenic-type in all eight mice. </plain></SENT>
<SENT sid="177" pm="."><plain>Next, we analyzed other markers near D6Mit149 using DNA from 70 mice (Figure 3A) and narrowed the responsible region to 27.3–32.2 cM (D6Mit384–D6Mit243), which was also associated with the phenotype of enhanced memantine susceptibility. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="genes-05-01095-f003" position="float"><label>Figure 3</label><caption><p><text><SENT sid="178" pm="."><plain>Identification of the responsible gene. </plain></SENT>
<SENT sid="179" pm="."><plain>(A) Microsatellite analyses of N2 mice. </plain></SENT>
<SENT sid="180" pm="."><plain>B6, parental allele of the ataxic mouse (C56BL/6J); C3, WT allele of C3H/HeN. </plain></SENT>
<SENT sid="181" pm="."><plain>N2 mice were produced following in vitro fertilization with oocytes from hetero N1 (B6/C3) and sperm from the original N0 ataxic B6 (B6/B6). </plain></SENT>
<SENT sid="182" pm="."><plain>Markers are described in the Experimental Section. </plain></SENT>
<SENT sid="183" pm="."><plain>Normal and Mut indicate mice with or without the ataxic phenotype, respectively. </plain></SENT>
<SENT sid="184" pm="."><plain>The Grid2 gene is located 29.77 cM in chromosome 6; (B) The full-length open reading frame ORF of Grid2 was amplified from cDNA prepared from the cerebellum of WT and Mut mice; (C) Western blotting for GRID2; (D) A diagram showing break points in the Grid2 gene of ataxic mice; (E) Putative protein sequence of GRID2 in Grid2Htake/Htake mice is predicted from diagram D and the direct ORF sequence. </plain></SENT>
</text></p></caption><graphic xlink:href="genes-05-01095-g003"/></fig></SecTag><p><text><SENT sid="185" pm="."><plain>When we searched for genes that have known associations with ataxic phenotypes, we noticed the Grid2 gene at 29.77 cM [30]. </plain></SENT>
<SENT sid="186" pm="."><plain>To determine whether this gene was responsible for the observed phenotype, the Grid2 open reading frame (ORF) was amplified from cDNA prepared from the cerebellum. </plain></SENT>
<SENT sid="187" pm="."><plain>As shown in Figure 3B, the Grid2 ORF was approximately 1 kb shorter in the mutant mice than in the WT mice. </plain></SENT>
<SENT sid="188" pm="."><plain>In addition, western blotting for GRID2 revealed that this protein was absent from the mutant cerebellum (Figure 3C). </plain></SENT>
</text></p><p><text><SENT sid="189" pm="."><plain>Direct sequencing of the mutant ORF suggested that the region from exon 3 to exon 8 might be deleted, which is the longest deletion reported in Grid2 mutant mice [31]. </plain></SENT>
<SENT sid="190" pm="."><plain>Chromosome walking (Figure 3D) identified the break points 110 kb upstream from exon 3 and 30 kb downstream from exon 8, which yielded a truncated GRID2 protein similar to that in the Grid2trp/trp, Grid2ho8J/ho8J, and Grid2ho13J/ho13J mutants, but with different flanking peptides (Figure 3E). </plain></SENT>
<SENT sid="191" pm="."><plain>Our laboratory code for mutant mouse lines is Htake, thus the mutant allele is named Grid2Htake. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="192" pm="."><plain>2.4. </plain></SENT>
<SENT sid="193" pm="."><plain>Altered Sensitivity to NMDA in Cultured Granule Cells of Grid2Htake/Htake Mice </plain></SENT>
</text></title><p><text><SENT sid="194" pm="."><plain>GRID2 is highly expressed in Purkinje cells, and disruption of GRID2 signaling impairs Purkinje cell functions. </plain></SENT>
<SENT sid="195" pm="."><plain>However, little or no expression of functional NMDA receptors in Purkinje cells of the adult cerebellum has been reported [32]. </plain></SENT>
<SENT sid="196" pm="."><plain>Thus, it is possible that Grid2 gene deletion influences cerebellar function by affecting NMDA receptors on granule cells. </plain></SENT>
<SENT sid="197" pm="."><plain>We examined whether Grid2Htake/Htake mice possessed memantine-sensitive NMDA receptors on cerebellar granule cells, using granule cell-enriched (Purkinje cell-free) primary cultures from P2 mice. </plain></SENT>
<SENT sid="198" pm="."><plain>Quantitative PCR (Figure 4A) and western blot analyses (Figure 4B) showed that cultured granule cells expressed low, but detectable, levels of Grid2 mRNA and GRID2 protein. </plain></SENT>
<SENT sid="199" pm="."><plain>No significant difference in NMDAR1 protein level was observed between the cultures derived from normal and Grid2Htake/Htake mice, which was consistent with the result of mRNA (microarray) analyses (Supplementary Table S1). </plain></SENT>
</text></p><p><text><SENT sid="200" pm="."><plain>We have to note, however, that no significant interaction between GRID2 protein and NMDAR1 protein in the total cerebella or cultured granule cell lysate was observed (Supplementary Figure S2), despite the presence of PKC gamma binding to GRID2 protein [33]. </plain></SENT>
</text></p><p><text><SENT sid="201" pm="."><plain>Next, we monitored NMDA-induced currents in cultured granule cells using a whole-cell voltage-clamp technique. </plain></SENT>
<SENT sid="202" pm="."><plain>At cell densities as low as 1.25 million cells/mL and a holding potential of −90 mV, granule cells from both WT and mutant mice showed no baseline activity (Figure 4C). </plain></SENT>
<SENT sid="203" pm="."><plain>In the absence of memantine (before memantine), NMDA (20 µM, 2 s) induced inward currents that were larger in WT cells than in mutant cells. </plain></SENT>
<SENT sid="204" pm="."><plain>Furthermore, NMDA-induced currents were reduced in the presence of memantine (after memantine: 10 µM, 30 s). </plain></SENT>
<SENT sid="205" pm="."><plain>However, the magnitude of the memantine-dependent suppression of the NMDA-induced currents varied in the individual cells. </plain></SENT>
</text></p><p><text><SENT sid="206" pm="."><plain>To accurately categorize the memantine-sensitive NMDA-induced currents, we divided the cells into two categories based on the ability of memantine to reduce the charge density of NMDA-induced currents by more than 75%. </plain></SENT>
<SENT sid="207" pm="."><plain>According to this classification, 51.9% of WT cells and only 21.4% of mutant cells were categorized as memantine-sensitive (Figure 4D). </plain></SENT>
<SENT sid="208" pm="."><plain>Moreover, the classification (only open circles) revealed that the values of charge density from the mutant cells fell into a lower range, which produced a significant difference in the variance of the charge density between the WT and mutant groups (Figure 4E). </plain></SENT>
<SENT sid="209" pm="."><plain>These results suggest that mutant mice might possess a poor variation of NMDA receptor with reduced function on their granule cell population. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="genes-05-01095-f004" position="float"><label>Figure 4</label><caption><p><text><SENT sid="210" pm="."><plain>NMDA-responsiveness of cultured cerebellar granule cells. </plain></SENT>
<SENT sid="211" pm="."><plain>(A) The raw data for quantitative PCR analyses and normalized levels (inset: n = 4) of Gird2 mRNA are indicated. </plain></SENT>
<SENT sid="212" pm="."><plain>Total RNA was prepared from total cerebellum, 2-week-cultured cerebellar granule cells from neonates (P2), B16F10 melanoma cells (non-neuronal negative control); (B) Western blotting was performed using WT and Grid2Htake/Htake (Mut) total cerebella or cultured granule cells. </plain></SENT>
<SENT sid="213" pm="."><plain>There is no significant difference in NMDAR1 protein level; (C) Whole-cell current responses of cultured granule cells derived from WT and Mut mice to local application of NMDA (20 µM, 2 s) before and after treatment with memantine (10 µM, 30 s). </plain></SENT>
<SENT sid="214" pm="."><plain>Representative currents recorded from single WT and Mut cells. </plain></SENT>
<SENT sid="215" pm="."><plain>Arrowheads indicate artifacts due to the opening and closure of the electromagnetic valve controlling delivery of NMDA-containing saline; (D) The examined cells were categorized into two groups by memantine susceptibility, and their populations are represented as % fractions. </plain></SENT>
<SENT sid="216" pm="."><plain>When more than 75% of NMDA-induced inward current was suppressed by memantine, the cells were categorized into the memantine-sensitive group (white area). </plain></SENT>
<SENT sid="217" pm="."><plain>Cells that experienced reduced inward current suppression after memantine treatment, or no significant inward current were categorized into the memantine-insensitive group (black area). * p = 0.0178, likelihood ratio test (WT, n = 27; Mut, n = 28); (E) Distribution of the total charge density of NMDA-induced inward currents. </plain></SENT>
<SENT sid="218" pm="."><plain>Open circles (white) and closed triangles (black) indicate the data from cells categorized as D. </plain></SENT>
<SENT sid="219" pm="."><plain>The magnitude of the total data (white and black) was not significantly different between the WT and mutant cells (medians, 1.01 and 0.64 pC/pF, respectively). </plain></SENT>
<SENT sid="220" pm="."><plain>However, in a comparison of the data from the memantine-sensitive cells (white), there was a significant difference in variance between the WT and mutant cells (* p = 0.0120, Brown-Forsythe test). </plain></SENT>
</text></p></caption><graphic xlink:href="genes-05-01095-g004"/></fig></SecTag></sec><sec><title><text><SENT sid="221" pm="."><plain>2.5. </plain></SENT>
<SENT sid="222" pm="."><plain>Mice Treated with Memantine and AMPA Were Unable to Walk Smoothly </plain></SENT>
</text></title><p><text><SENT sid="223" pm="."><plain>GRID2 deficiency results in dysregulation of AMPA receptors [34,35]. </plain></SENT>
<SENT sid="224" pm="."><plain>To examine whether impaired AMPA receptor functions affected memantine susceptibility, mice were treated with memantine simultaneously with the AMPA receptor agonist AMPA or the antagonist DNQX [36], and the movements of these mice were monitored (Figure 5A). </plain></SENT>
<SENT sid="225" pm="."><plain>The mice treated with AMPA (20 mg/kg) walked slowly and sometimes crouched on the floor. </plain></SENT>
<SENT sid="226" pm="."><plain>However, mice treated with both memantine (10 mg/kg) and AMPA had increased activity and did not stop walking. </plain></SENT>
<SENT sid="227" pm="."><plain>In addition to these abnormal behaviors, the mice walked with a mild staggering gait and sometimes slipped (roll-over: Figure 5B, Supplementary Movie 4). </plain></SENT>
<SENT sid="228" pm="."><plain>These combined effects of memantine on mouse behavior were not observed when memantine was administered with DNQX (10 mg/kg), although the mice treated with DNQX were also sometimes crouched. </plain></SENT>
<SENT sid="229" pm="."><plain>Moreover, in the Grid2Htake/Htake mice, co-treatment with AMPA and a low dose of memantine (5 mg/kg) caused more evident balance impairment than memantine treatment alone (Supplementary Figure S3), suggesting that GRID2 deficiency may augment the synergistic action of AMPA and memantine. </plain></SENT>
<SENT sid="230" pm="."><plain>The effect of AMPA co-treatment could not be evaluated with a higher dose of memantine (10 mg/kg) because the maximal effect was induced by this dose of memantine. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="genes-05-01095-f005" position="float"><label>Figure 5</label><caption><p><text><SENT sid="231" pm="."><plain>Effect of AMPA receptor modulators on memantine action in WT mice. </plain></SENT>
<SENT sid="232" pm="."><plain>(A) Monitoring of walking mice (12-week-old WT male, n = 6) after memantine treatment (10 mg/kg) combined with AMPA (20 mg/kg) or the AMPA receptor antagonist DNQX (10 mg/kg). </plain></SENT>
<SENT sid="233" pm="."><plain>Ten minutes after the treatments, the walking distance for 5 min was expressed as the mean and SD, * p &lt; 0.05 vs. the other conditions (unpaired t-test; p &lt; 0.0001 for overall differences, one-way ANOVA); (B) Number of rollovers in 5 min was counted. </plain></SENT>
<SENT sid="234" pm="."><plain>NO indicates that rollover was not observed. n = 6 for Control and AMPA + memantine and n = 3 for the other conditions. </plain></SENT>
<SENT sid="235" pm="."><plain>The occurrence of rollover was significantly different between AMPA + memantine and the other conditions (p &lt; 0.05, Fisher’s exact test); (C) OKRs measured in female WT mice with sequential injections of the control saline, AMPA (10 mg/kg), or DNQX (5 mg/kg) and memantine (5 mg/kg). </plain></SENT>
<SENT sid="236" pm="."><plain>A set of traces indicates representative responses of individual mice. </plain></SENT>
<SENT sid="237" pm="."><plain>Dotted line, the movement of the stimulus screen; (D) Graph shows the mean and ±SD of OKR gain (n = 3 for each condition). p value (without a bracket, one-tailed unpaired t-test; with brackets, paired t-test) is indicated when significance was observed. </plain></SENT>
</text></p></caption><graphic xlink:href="genes-05-01095-g005a"/><graphic xlink:href="genes-05-01095-g005b"/></fig></SecTag><p><text><SENT sid="238" pm="."><plain>Finally, the OKR was monitored after co-treatment with memantine and AMPA or DNQX (Figure 5C). </plain></SENT>
<SENT sid="239" pm="."><plain>Mice were first treated with AMPA, DNQX, or saline, and the OKR was subsequently monitored for 5 min (because some mice closed their eyes after treatment with higher doses, AMPA (10 mg/kg) and DNQX (5 m/kg) were used for OKR measurement). </plain></SENT>
<SENT sid="240" pm="."><plain>To evaluate synergies between memantine and AMPA receptor modulators, the mice were further treated with a low dose of memantine (5 mg/kg), and again subjected to OKR measurements for another 5 min. </plain></SENT>
<SENT sid="241" pm="."><plain>AMPA significantly impaired the OKR, and the combined treatment with memantine further impaired the OKR (Figure 5D). </plain></SENT>
<SENT sid="242" pm="."><plain>These effects were not observed in mice co-treated with memantine and DNQX. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec><title><text><SENT sid="243" pm="."><plain>3. </plain></SENT>
<SENT sid="244" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="245" pm="."><plain>Here, we report cross-talk between GRID2 signaling and memantine in mice, which may, in part, account for the adverse effects of memantine in patients with individual differences in congenital or acquired genetic factors, such as GRID2. </plain></SENT>
</text></p><p><text><SENT sid="246" pm="."><plain>Major phenotypes have been identified in GRID2 mutant mice, including impaired motor coordination, learning, and memory. </plain></SENT>
<SENT sid="247" pm="."><plain>GRID2 is located on the postsynaptic membrane of Purkinje cells and binds to cerebellin precursor protein 1 (CBLN1) and neurexin 1 beta (NRXN1b) [7,8] on the parallel fibers of granule cells [7,37]. </plain></SENT>
<SENT sid="248" pm="."><plain>On the other hand, the memantine target, NMDA receptors, are also expressed on the developing [38] and adult [39] cerebellar granule cells. </plain></SENT>
<SENT sid="249" pm="."><plain>Furthermore, contrary to the neurotoxic effects of glutamate, NMDA receptors were found to promote the survival of cultured Purkinje [40] and granule cells [41,42]. </plain></SENT>
<SENT sid="250" pm="."><plain>However, double-KO mice with disrupted Nr2A and Nr2C genes (encoding two major NMDA receptor subunits in the adult mice cerebellum) demonstrate a mild impairment in motor coordination, but they do not exhibit an ataxic phenotype [43]. </plain></SENT>
<SENT sid="251" pm="."><plain>This observation suggests that NMDA receptors and GRID2 functions may not be directly linked [44]. </plain></SENT>
</text></p><p><text><SENT sid="252" pm="."><plain>Thus, in the present study, pharmaco-behavioral approaches failed to identify Grid2 as a candidate for the cause of the observed phenotypes. </plain></SENT>
<SENT sid="253" pm="."><plain>Unexpectedly, our efforts resulted in the observation of new phenotypes in our Grid2 deficient mice, which appeared as enhanced memantine susceptibility, which was likely mediated by dysfunctional NMDA receptors [1,2,45]. </plain></SENT>
<SENT sid="254" pm="."><plain>OKR measurements in Grid2Htake/Htake mice revealed impaired basal cerebellar functions in eye movement, which was also mimicked by memantine treatment. </plain></SENT>
<SENT sid="255" pm="."><plain>Dizziness has been reported as a major adverse effect of memantine treatment in humans [6,46]. </plain></SENT>
<SENT sid="256" pm="."><plain>The cerebellar flocculus is thought to be responsible for the early stage formation of OKR adaptation and its memory [47,48]. </plain></SENT>
</text></p><p><text><SENT sid="257" pm="."><plain>The Grid2 gene is located in a hot spot of genomic deletions [31], and a number of mutant lines with defects in this gene have been identified. </plain></SENT>
<SENT sid="258" pm="."><plain>In addition to naturally occurring mutants, targeted disruption and knock-in mutations of Grid2 have been reported [30,49,50]. </plain></SENT>
<SENT sid="259" pm="."><plain>In contrast to these loss-of-function mutations, Grid2Lc (Lurcher) [51] was identified as a spontaneous dominant mutation characterized by cerebellar ataxia and atrophy of Purkinje and granule cells [30]. </plain></SENT>
<SENT sid="260" pm="."><plain>Physiological studies of Grid2Lc/+ mice have shown that the Grid2Lc mutation produces constitutive inward Ca2+/Na+ currents that induce cell death [52]. </plain></SENT>
</text></p><p><text><SENT sid="261" pm="."><plain>The importance of the genetic background on Grid2Lc/+ mice phenotypes was also reported [47,53]. </plain></SENT>
<SENT sid="262" pm="."><plain>In congenic Grid2Lc/+ mice, almost 99.99% of those on a C57BL/6 genetic background lost Purkinje cells, whereas no Purkinje cell loss was observed in Grid2Lc/+ mice on a 93% C57BL/6 genetic background, indicating that phenotypes in Grid2Lc/+ mice are highly dependent on their genetic backgrounds. </plain></SENT>
<SENT sid="263" pm="."><plain>Interestingly, abnormal eye-movement and impaired motor-coordination were only observed in 93% of C57BL/6 background-Grid2Lc/+ mice possessing Purkinje cells, but not in 99.99% of C57BL/6 background-Grid2Lc/+ mice without Purkinje cells [47], suggesting that gain of GRID2 signaling is also a cause of motor deficits in the presence of Purkinje cells. </plain></SENT>
<SENT sid="264" pm="."><plain>In contrast to Grid2Lc/+ mice, we noticed during gene mapping that memantine-induced balance impairment was observed in Grid2Htake/Htake mice irrespective of their genetic backgrounds (mixed B6 and C3 backgrounds). </plain></SENT>
<SENT sid="265" pm="."><plain>This is also the case for random eye movements commonly observed in different Grid2-deleted mice with different genetic backgrounds, Grid2-KO in C57BL/6 and Grid2ho-15J/15J on a C3HJ background [17], suggested that memantine-induced balance impairment may occur in other Grid2 deficient mice irrespective of their genetic backgrounds. </plain></SENT>
</text></p><p><text><SENT sid="266" pm="?"><plain>How does the Grid2Htake deletion enhance the actions of memantine? </plain></SENT>
<SENT sid="267" pm="."><plain>GRID2 regulates long-term depression (LTD) at synapses between immature parallel fibers and Purkinje cells by inducing AMPA receptor endocytosis [34,35]. d-Serine is an endogenous ligand for GRID2 and one of the factors that induce LTD [9]. </plain></SENT>
<SENT sid="268" pm="."><plain>Developing mice that express GRID2 with a disrupted d-serine binding site show impaired motor coordination and learning, suggesting the importance of LTD for motor regulation. </plain></SENT>
<SENT sid="269" pm="."><plain>On the other hand, NMDA receptor activation requires the removal of Mg2+ block, which occurs when the membrane potential increases through activation of non-NMDA receptors including AMPA receptors [4]. </plain></SENT>
<SENT sid="270" pm="."><plain>Cooperative signal-transmission from cerebellar mossy fiber-granule cells to Purkinje cells mediated by NMDA and AMPA receptors has been shown in both Mg2+ block dependent and independent manners [54]. </plain></SENT>
<SENT sid="271" pm="."><plain>We observed that co-treatment with memantine and AMPA impaired gait and OKR in wild type mice, suggesting that dysregulation of AMPA receptor function in Grid2 deficient mice may cause the enhanced memantine susceptibility. </plain></SENT>
<SENT sid="272" pm="."><plain>This may be implicated in the decreased number of memantine-sensitive NMDA-responsible granule cells in Grid2Htake/Htake mice. </plain></SENT>
</text></p><p><text><SENT sid="273" pm="."><plain>Whilst mapping the gene responsible for the ataxic phenotype, we observed new phenotypes in Grid2 deficient mice, which were latent balance defects, and OKR impairments. </plain></SENT>
<SENT sid="274" pm="."><plain>These deficits were also mimicked by memantine with AMPA in the impaired WT mice. </plain></SENT>
<SENT sid="275" pm="."><plain>Because, recently, the wide distributions of Grid2 mRNA and GRID2 protein were reported in the adult rodent brain [55], the phenotypes in Grid2Htake/Htake mice could be ascribed to not only attenuated NMDA receptor responsiveness in a subset of granule cells but also other cellular mechanisms. </plain></SENT>
</text></p><p><text><SENT sid="276" pm="."><plain>When granule cells are collectively activated in vivo, glutamate spilt over from parallel fiber-Purkinje cell synapses stimulate adjacent interneurons (volume transmission), which in turn exert inhibition of Purkinje cells [44,56,57,58] crucial for normal motor coordination [59]. </plain></SENT>
<SENT sid="277" pm="."><plain>The GRID2 mutation may reduce NMDA receptor-mediated excitation of granule cells, and this might decrease the volume transmission and Purkinje cell inhibition via interneurons. </plain></SENT>
<SENT sid="278" pm="."><plain>Moreover, cerebellar interneurons (basket, stellate, and Golgi cells) also express functional NMDA receptors at their presynaptic membrane [44,56,57,58] and these receptors could be affected by the change of GRID2 signaling. </plain></SENT>
<SENT sid="279" pm="."><plain>Taken as a whole, the present study using a naturally occurring Grid2 deleted mouse line may lead to a better understanding of NMDA, AMPA, and GRID2 receptors. </plain></SENT>
<SENT sid="280" pm="."><plain>Further studies are required to elucidate the precise mechanisms underlying GRID2 signaling. </plain></SENT>
</text></p></sec></SecTag><sec><title><text><SENT sid="281" pm="."><plain>4. </plain></SENT>
<SENT sid="282" pm="."><plain>Experimental Section </plain></SENT>
</text></title><sec><title><text><SENT sid="283" pm="."><plain>4.1. </plain></SENT>
<SENT sid="284" pm="."><plain>Animals </plain></SENT>
</text></title><p><text><SENT sid="285" pm="."><plain>C57BL/6J (B6) and C3H/HeN (C3) from SLC Japan (Shizuoka, JAPAN) were used for the maintenance of the Grid2Htake/Htake mouse line and for IVF for microsatellite analyses, respectively. </plain></SENT>
<SENT sid="286" pm="."><plain>IVF was performed following a standard method [60] using human tubal fluid medium (Ark Resource, Kumamoto, Japan). </plain></SENT>
<SENT sid="287" pm="."><plain>The Grid2 mutant mice, Grid2Htake/Htake (formal name is Grid2ho-Htake/Nibio), were supplied by the JCRB Laboratory Animal Resource Bank at the National Institute of Biomedical Innovation. </plain></SENT>
<SENT sid="288" pm="."><plain>The experimental mouse protocols were approved by the Ethics Committee at the National Institute of Biomedical Innovation (assigned No. </plain></SENT>
<SENT sid="289" pm="."><plain>DS-23-35), and by the University of Toyama’s Committee on Animal Experiments (assigned No. A2012eng-8) for animal welfare. </plain></SENT>
<SENT sid="290" pm="."><plain>For microarray analyses, cerebella were dissected after anesthesia of mice with isoflurane (WAKO Pure Chemicals, Osaka, JAPAN). </plain></SENT>
<SENT sid="291" pm="."><plain>The animals were maintained under standard light (08:00–20:00) and temperature conditions (23 °C, 50% humidity). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="292" pm="."><plain>4.2. </plain></SENT>
<SENT sid="293" pm="."><plain>Reagents </plain></SENT>
</text></title><p><text><SENT sid="294" pm="."><plain>Microsatellite markers were used to identify the chromosomal region responsible for the ataxic phenotype, (D6Mit86, 1.18 cM; D6Mit351, 22.94 cM; D6Mit384, 27.38 cM; D6Mit243, 32.2 cM 7; D6Mit29, 37.75 cM; D6Mit102. </plain></SENT>
<SENT sid="295" pm="."><plain>42.11 cM; D6Mit149, 48.93 cM; D6Mit200, 89.28 cM). </plain></SENT>
<SENT sid="296" pm="."><plain>To map the end points of the Grid2 deletion, we used following primers: mGrid2 intron 2H F 5'-GCT ACT TTG GTA CAA GTG GAC A and mGrid2 intron 2H R 5'-GAC AAG TTG CTC TCT GTA TCT; mGrid2 Intron 2I F 5'-CAT GCT CAC ATC AAA ATA CAT CAA and mGrid2 Intron 2I R 5'-TGT AAT TGA GGAA AAT ACA TAA T. </plain></SENT>
<SENT sid="297" pm="."><plain>Other primers used in Figure 3D were prepared with reference to [31]. </plain></SENT>
<SENT sid="298" pm="."><plain>To identify the Grid2 deletion in Grid2Htake/Htake mice, we used the following primers for PCR amplification: mGrid2 Intron 2HIF 5'-TGG ATC CTT CTA CGT GCA AC, mGrid2 Intron 8YF2 5'-GGA CCA CAC TGA GGT TCG AAA GA, and mGrid2 Intron 8YR 5'-ATC TCT TGG CAT GCA TTA GAC. </plain></SENT>
<SENT sid="299" pm="."><plain>The mutant allele of Grid2Htake produces a PCR band corresponding to a product of approximately 600 bp, and that for the WT allele is approximately 400 bp. </plain></SENT>
</text></p><p><text><SENT sid="300" pm="."><plain>GRID2 antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). </plain></SENT>
<SENT sid="301" pm="."><plain>Antibodies for NMDAR1 and tubulin were obtained from Cell Signaling Technology (Boston, MA, USA). </plain></SENT>
<SENT sid="302" pm="."><plain>Memantine, AMPA, DNQX, MK-801, nitrazepam, donepezil, and ondansetron were purchased from WAKO Pure Chemicals; ifenprodil, Ro25-6981, DL-AP7, felbamate, and loperamide were obtained from Sigma-Aldrich (St. Louis, MO, USA). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="303" pm="."><plain>4.3. </plain></SENT>
<SENT sid="304" pm="."><plain>mRNA Analyses </plain></SENT>
</text></title><p><text><SENT sid="305" pm="."><plain>Total RNA was prepared from the cerebellar hemispheres of 12-week-old mice (male and female) using the EZ1-RNA purification kit (Qiagen, Venlo Park, The Netherlands). </plain></SENT>
<SENT sid="306" pm="."><plain>For microarray analyses, GeneChip Mouse Genome 430A (Affymetrix, Santa Clara, CA, USA) was used, and differences in transcript levels were calculated with Partek (Partek Inc., St. Louis, MO, USA). </plain></SENT>
<SENT sid="307" pm="."><plain>The original data files (CEL-files) were deposited in the Gene Expression Omnibus (GEO) repository and assigned the GEO accession numbers: GSM1334015, GSM1334016, and GSM1334017 for normal mice, and GSM1334018, GSM1334019, and GSM1334020 for mutant mice. </plain></SENT>
<SENT sid="308" pm="."><plain>PCR primers for real-time PCR were as follows: mGrid2 F, 5'-AAC ACG CTA CAT GGA CTA CTC-3' and mGrid2 R, 5'-GAA GCA CTG TGC CAG CAA TG-3'; mGapdh F, 5'-ACT CAC GGC AAA TTC AAC GG-3' and mGapdh R, 5'-GAC TCC ACG ACA TAC TGA GC-3'. </plain></SENT>
<SENT sid="309" pm="."><plain>To amplify the Grid2 ORF, primers are mGrid2 F2 (5ATG): 5'-ATG GAA GTT TTC CCC TTG CTC TTG T and mGrid2 R (3Stop): 5'-TCA TAT GGA CGT GCC TCG GTC GGG GTC A were used. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="310" pm="."><plain>4.4. </plain></SENT>
<SENT sid="311" pm="."><plain>Measurements of Walking Distance and the OKR </plain></SENT>
</text></title><p><text><SENT sid="312" pm="."><plain>Male mice (12–14 weeks old) were placed in a rectangular box (25 cm × 40 cm), and their head position was tracked for 5 min using ANY-maze software (Brain Science Idea, Osaka, Japan). </plain></SENT>
<SENT sid="313" pm="."><plain>Each mouse was monitored three times, and the longest distance recorded was used in the data analysis. </plain></SENT>
</text></p><p><text><SENT sid="314" pm="."><plain>The OKR was measured in adult mice using previously described methods [28], which are depicted in Supplementary Figure S1. </plain></SENT>
<SENT sid="315" pm="."><plain>Briefly, the mice were anesthetized with isoflurane (2%) and a stainless steel screw was glued to the skull. </plain></SENT>
<SENT sid="316" pm="."><plain>The mice were then habituated to the experimental conditions for 2 days before the measurement. </plain></SENT>
<SENT sid="317" pm="."><plain>Ten minutes before the measurement were made, mice were administered a saline (8 mL/kg) injection with or without memantine (10 mg/kg) intraperitoneally. </plain></SENT>
<SENT sid="318" pm="."><plain>The mouse was then mounted on a stereotaxic apparatus and exposed to continuous sinusoidal horizontal oscillations (17°, 0.25 Hz) of a cylindrical checkerboard-patterned screen (diameter, 65 cm; single square, 1.8 × 1.8 cm; brightness, ~30 lx). </plain></SENT>
<SENT sid="319" pm="."><plain>Right eye movement was captured at 30 Hz with an infrared camera. </plain></SENT>
<SENT sid="320" pm="."><plain>For each image frame, we used a machine vision system to estimate the pupil azimuth from the location of the pupil center. </plain></SENT>
<SENT sid="321" pm="."><plain>The OKR was expressed on a time plot of the relative pupil azimuth for each round of screen oscillation, with the pupil azimuth at the beginning of backward eye movement set to 0°. </plain></SENT>
<SENT sid="322" pm="."><plain>An OKR gain was defined as the ratio of the maximal relative pupil azimuth change to that of the screen (17°). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="323" pm="."><plain>4.5. </plain></SENT>
<SENT sid="324" pm="."><plain>Cell Culture and Electrophysiology </plain></SENT>
</text></title><p><text><SENT sid="325" pm="."><plain>Granule cell-enriched cultures were prepared as previously described [61]. </plain></SENT>
<SENT sid="326" pm="."><plain>Briefly, 2-day-old (P2) mutant or WT mice were anesthetized by cooling and then sacrificed by decapitation. </plain></SENT>
<SENT sid="327" pm="."><plain>The cerebella were dissociated with trypsin, plated on poly-l-ornithine-coated plastic dishes (Becton Dickinson, Franklin Lakes, NJ, USA) at 1.25 million cells/mL, and maintained in low-serum, nutrient-supplemented Dulbecco’s Modified Eagle Medium/F-12 (Life Technologies; 5% CO2, 37 °C) for 12 days. </plain></SENT>
</text></p><p><text><SENT sid="328" pm="."><plain>Ruptured-patch whole-cell recordings were performed on cultured granule cells. </plain></SENT>
<SENT sid="329" pm="."><plain>The pipette solution contained 134 mM potassium d-gluconic acid, 7.6 mM KCl, 9 mM KOH, 10 mM NaCl, 1.2 mM MgCl2, 4 mM ATP magnesium salt, 10 mM HEPES, and 0.5 mM EGTA (pH 7.3). </plain></SENT>
<SENT sid="330" pm="."><plain>The culture dish was perfused at a rate of 1.4 mL/min with 145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 10 mM HEPES, 10 mM d-glucose, and 10 µM glycine (pH 7.4). </plain></SENT>
<SENT sid="331" pm="."><plain>Current signals were recorded using an EPC-8 amplifier (holding potential, −90 mV; cut-off frequency, 5 kHz; sampling rate, 20 kHz; HEKA, Lambrecht/Pfalz, Germany) controlled by Patchmaster software (version, 2.35; HEKA). </plain></SENT>
<SENT sid="332" pm="."><plain>The command potentials were corrected for a liquid junction potential between the pipette and bath solutions. </plain></SENT>
<SENT sid="333" pm="."><plain>Electronic capacitance cancellation and series resistance compensation were not used. </plain></SENT>
<SENT sid="334" pm="."><plain>The series resistance (33.2 ± 5.1 MΩ, n = 55) and membrane capacitance were estimated from the amplitude and time constant of the capacitive current evoked by a 10 mV voltage jump. </plain></SENT>
<SENT sid="335" pm="."><plain>The bath solution containing 20 µM NMDA or 10 µM memantine was locally applied to the cell through a theta tube under the control of gravity and electromagnetic valves (VM8, ALA Scientific Instruments, Farmingdale, NY, USA). </plain></SENT>
<SENT sid="336" pm="."><plain>The magnitude of an NMDA-induced current was quantified as the inward current charge over a 2 s NMDA application normalized to the membrane capacitance (charge density). </plain></SENT>
<SENT sid="337" pm="."><plain>The background charge was estimated from a 0.5 s pre-application period and subtracted from the charge density. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="338" pm="."><plain>4.6. </plain></SENT>
<SENT sid="339" pm="."><plain>Statistical Analyses </plain></SENT>
</text></title><p><text><SENT sid="340" pm="."><plain>Data from each group were characterized by the mean ± SD, unless otherwise stated. </plain></SENT>
<SENT sid="341" pm="."><plain>Data from biochemical assays were examined with one-way ANOVA followed by unpaired two-tailed t-tests to detect statistically significant differences. </plain></SENT>
<SENT sid="342" pm="."><plain>All the statistical examinations were performed using JMP software (versions 9.0.2 and 10.0.1, SAS Institute, Cary, NC, USA). </plain></SENT>
</text></p></sec></sec></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="343" pm="."><plain>We thank Junko Morita for her technical assistance and Takayoshi Imazawa for their kind advice. </plain></SENT>
<SENT sid="344" pm="."><plain>We thank Sebnem Kesaf and Ryuichi Shigemoto for their advice on performing OKR measurements. </plain></SENT>
</text></text4fund></p><p><text4fund><text><SENT sid="345" pm="."><plain>This study was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (25670155, 23500384, 23500384); the grant from the Ministry of Health, Labor, and Welfare (2013–2017, 2014–2016); Scientific Research on Innovative Areas, a MEXT Grant-in-Aid Project 2012–2013; Strategic Research Foundation at Private Universities (2013–2017); the grant from the Human Science Foundation (2012–2013); and a grant from the Uehara Memorial Foundation. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="APPENDIX"><app-group><app><title>Supplementary Files</title><supplementary-material content-type="local-data" id="genes-05-01095-s001"><label>Supplementary File 1</label><media xlink:href="genes-05-01095-s001.rar"><caption><p><text><SENT sid="346" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></app></app-group></SecTag><notes><title>Author Contributions</title><p>A.K., A.F., T.Y., Y.N., Y.H., T.S., Y.I., M.K., O.S., S.A, H.R., A.K., L.P.T, M.S., T.F., H.T. performed experiments. K.K., Y.N., H.K., K.M., T.N., J.M. T.T., H.T. analyzed data. T.T., H.T. wrote the manuscript.</p></notes><notes><title>Conflicts of Interest</title><p>No conflicts of interest, financial or otherwise, are declared by the author(s).</p></notes><SecTag type="REF"><ref-list><title>References</title><ref id="B1-genes-05-01095"><text><SENT sid="347" pm="."><plain>1. SonkusareS.K.KaulC.L.RamaraoP. Dementia of Alzheimer’s disease and other neurodegenerative disorders—Memantine, a new hope Pharmacol. </plain></SENT>
<SENT sid="348" pm="."><plain>Res. 2005 51 1 17 10.1016/j.phrs.2004.05.005 15519530 </plain></SENT>
</text></ref><ref id="B2-genes-05-01095"><text><SENT sid="349" pm="."><plain>2. LiptonS.A. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond Nat. </plain></SENT>
<SENT sid="350" pm="."><plain>Rev. </plain></SENT>
<SENT sid="351" pm="."><plain>Drug Discov. 2006 5 160 170 10.1038/nrd1958 <?supplied-pmid 16424917?>16424917 </plain></SENT>
</text></ref><ref id="B3-genes-05-01095"><text><SENT sid="352" pm="."><plain>3. SzczurowskaE.MaresP. NMDA and AMPA receptors: Development and status epilepticus Physiol. </plain></SENT>
<SENT sid="353" pm="."><plain>Res. 2013 62 Suppl. </plain></SENT>
<SENT sid="354" pm="."><plain>1 S21 S38 <?supplied-pmid 23590611?>24329701 </plain></SENT>
</text></ref><ref id="B4-genes-05-01095"><text><SENT sid="355" pm="."><plain>4. KupperJ.AscherP.NeytonJ. Probing the pore region of recombinant N-methyl-d-aspartate channels using external and internal magnesium block Proc. </plain></SENT>
<SENT sid="356" pm="."><plain>Natl. </plain></SENT>
<SENT sid="357" pm="."><plain>Acad. </plain></SENT>
<SENT sid="358" pm="."><plain>Sci. </plain></SENT>
<SENT sid="359" pm="."><plain>USA 1996 93 8648 8653 10.1073/pnas.93.16.8648 <?supplied-pmid 8710925?>8710925 </plain></SENT>
</text></ref><ref id="B5-genes-05-01095"><text><SENT sid="360" pm="."><plain>5. WongE.H.KempJ.A.PriestleyT.KnightA.R.WoodruffG.N.IversenL.L. The anticonvulsant MK-801 is a potent N-methyl-d-aspartate antagonist Proc. </plain></SENT>
<SENT sid="361" pm="."><plain>Natl. </plain></SENT>
<SENT sid="362" pm="."><plain>Acad. </plain></SENT>
<SENT sid="363" pm="."><plain>Sci. </plain></SENT>
<SENT sid="364" pm="."><plain>USA 1986 83 7104 7108 10.1073/pnas.83.18.7104 <?supplied-pmid 3529096?>3529096 </plain></SENT>
</text></ref><ref id="B6-genes-05-01095"><text><SENT sid="365" pm="."><plain>6. HansenR.A.GartlehnerG.LohrK.N.KauferD.I. Functional outcomes of drug treatment in Alzheimer’s disease: A systematic review and meta-analysis Drugs Aging 2007 24 155 167 10.2165/00002512-200724020-00007 <?supplied-pmid 17313203?>17313203 </plain></SENT>
</text></ref><ref id="B7-genes-05-01095"><text><SENT sid="366" pm="."><plain>7. UemuraT.LeeS.J.YasumuraM.TakeuchiT.YoshidaT.RaM.TaguchiR.SakimuraK.MishinaM. Trans-synaptic interaction of GluRdelta2 and Neurexin through Cbln1 mediates synapse formation in the cerebellum Cell 2010 141 1068 1079 10.1016/j.cell.2010.04.035 <?supplied-pmid 20537373?>20537373 </plain></SENT>
</text></ref><ref id="B8-genes-05-01095"><text><SENT sid="367" pm="."><plain>8. MatsudaK.MiuraE.MiyazakiT.KakegawaW.EmiK.NarumiS.FukazawaY.Ito-IshidaA.KondoT.ShigemotoR. Cbln1 is a ligand for an orphan glutamate receptor delta2, a bidirectional synapse organizer Science 2010 328 363 368 10.1126/science.1185152 <?supplied-pmid 20395510?>20395510 </plain></SENT>
</text></ref><ref id="B9-genes-05-01095"><text><SENT sid="368" pm="."><plain>9. KakegawaW.MiyoshiY.HamaseK.MatsudaS.MatsudaK.KohdaK.EmiK.MotohashiJ.KonnoR.ZaitsuK. d-Serine regulates cerebellar LTD and motor coordination through the delta2 glutamate receptor Nat. </plain></SENT>
<SENT sid="369" pm="."><plain>Neurosci. 2011 14 603 611 10.1038/nn.2791 <?supplied-pmid 21460832?>21460832 </plain></SENT>
</text></ref><ref id="B10-genes-05-01095"><text><SENT sid="370" pm="."><plain>10. JardonB.BonaventureN. N-Methyl-d-aspartate antagonists suppress the development of frog symmetric monocular optokynetic nystagmus observed after unilateral visual deprivation Brain Res. </plain></SENT>
<SENT sid="371" pm="."><plain>Dev. </plain></SENT>
<SENT sid="372" pm="."><plain>Brain Res. 1992 67 67 73 10.1016/0165-3806(92)90026-S <?supplied-pmid 1353422?>1353422 </plain></SENT>
</text></ref><ref id="B11-genes-05-01095"><text><SENT sid="373" pm="."><plain>11. GodauxE.CheronG.MettensP. Ketamine induces failure of the oculomotor neural integrator in the cat Neurosci. </plain></SENT>
<SENT sid="374" pm="."><plain>Lett. 1990 116 162 167 10.1016/0304-3940(90)90403-V <?supplied-pmid 2259445?>2259445 </plain></SENT>
</text></ref><ref id="B12-genes-05-01095"><text><SENT sid="375" pm="."><plain>12. MettensP.CheronG.GodauxE. NMDA receptors are involved in temporal integration in the oculomotor system of the cat Neuroreport 1994 5 1333 1336 <?supplied-pmid 7919192?>7919192 </plain></SENT>
</text></ref><ref id="B13-genes-05-01095"><text><SENT sid="376" pm="."><plain>13. HuangY.J.LinC.H.LaneH.Y.TsaiG.E. NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer’s Disease Curr. </plain></SENT>
<SENT sid="377" pm="."><plain>Neuropharmacol. 2012 10 272 285 10.2174/157015912803217288 <?supplied-pmid 23450042?>23450042 </plain></SENT>
</text></ref><ref id="B14-genes-05-01095"><text><SENT sid="378" pm="."><plain>14. PuangthongU.HsiungG.Y. Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease Neuropsychiatr. </plain></SENT>
<SENT sid="379" pm="."><plain>Dis. </plain></SENT>
<SENT sid="380" pm="."><plain>Treat. 2009 5 553 561 <?supplied-pmid 19898670?>19898670 </plain></SENT>
</text></ref><ref id="B15-genes-05-01095"><text><SENT sid="381" pm="."><plain>15. UtineG.E.HalilogluG.SalanciB.CetinkayaA.KiperP.O.AlanayY.AktasD.BodurogluK.AlikasifogluM. A Homozygous Deletion in GRID2 Causes a Human Phenotype With Cerebellar Ataxia and Atrophy J. </plain></SENT>
<SENT sid="382" pm="."><plain>Child Neurol. 2013 28 926 932 10.1177/0883073813484967 <?supplied-pmid 23611888?>23611888 </plain></SENT>
</text></ref><ref id="B16-genes-05-01095"><text><SENT sid="383" pm="."><plain>16. MaierA.KlopockiE.HornD.TzschachA.HolmT.MeyerR.MeyerT. De novo partial deletion in GRID2 presenting with complicated spastic paraplegia Muscle Nerve 2014 49 289 292 10.1002/mus.24096 <?supplied-pmid 24122788?>24122788 </plain></SENT>
</text></ref><ref id="B17-genes-05-01095"><text><SENT sid="384" pm="."><plain>17. HillsL.B.MasriA.KonnoK.KakegawaW.LamA.T.Lim-MeliaE.ChandyN.HillR.S.PartlowJ.N.Al-SaffarM. Deletions in GRID2 lead to a recessive syndrome of cerebellar ataxia and tonic upgaze in humans Neurology 2013 81 1378 1386 10.1212/WNL.0b013e3182a841a3 <?supplied-pmid 24078737?>24078737 </plain></SENT>
</text></ref><ref id="B18-genes-05-01095"><text><SENT sid="385" pm="."><plain>18. Van SchilK.MeireF.KarlstetterM.BauwensM.VerdinH.CoppietersF.ScheiffertE.van NechelC.LangmannT.DeconinckN. Early-onset autosomal recessive cerebellar ataxia associated with retinal dystrophy: New human hotfoot phenotype caused by homozygous GRID2 deletion Genet. </plain></SENT>
<SENT sid="386" pm="."><plain>Med. 2014 10.1038/gim.2014.95  </plain></SENT>
</text></ref><ref id="B19-genes-05-01095"><text><SENT sid="387" pm="."><plain>19. UebiT.ItohY.HatanoO.KumagaiA.SanosakaM.SasakiT.SasagawaS.DoiJ.TatsumiK.MitamuraK. Involvement of SIK3 in glucose and lipid homeostasis in mice PLOS ONE 2012 7 e37803 10.1371/journal.pone.0037803 <?supplied-pmid 22662228?>22662228 </plain></SENT>
</text></ref><ref id="B20-genes-05-01095"><text><SENT sid="388" pm="."><plain>20. HemmingsH.C.Jr.YanW.WestphalenR.I.RyanT.A. The general anesthetic isoflurane depresses synaptic vesicle exocytosis Mol. </plain></SENT>
<SENT sid="389" pm="."><plain>Pharmacol. 2005 67 1591 1599 10.1124/mol.104.003210 <?supplied-pmid 15728262?>15728262 </plain></SENT>
</text></ref><ref id="B21-genes-05-01095"><text><SENT sid="390" pm="."><plain>21. RammesG.DanyszW.ParsonsC.G. Pharmacodynamics of memantine: An update Curr. </plain></SENT>
<SENT sid="391" pm="."><plain>Neuropharmacol. 2008 6 55 78 10.2174/157015908783769671 <?supplied-pmid 19305788?>19305788 </plain></SENT>
</text></ref><ref id="B22-genes-05-01095"><text><SENT sid="392" pm="."><plain>22. SeemanP.CarusoC.LasagaM. Memantine agonist action at dopamine D2High receptors Synapse 2008 62 149 153 10.1002/syn.20472 <?supplied-pmid 18000814?>18000814 </plain></SENT>
</text></ref><ref id="B23-genes-05-01095"><text><SENT sid="393" pm="."><plain>23. LeeJ.W.ParkH.J.ChoiJ.ParkS.J.KangH.KimE.G. Comparison of ramosetron’s and ondansetron’s preventive anti-emetic effects in highly susceptible patients undergoing abdominal hysterectomy Korean J. </plain></SENT>
<SENT sid="394" pm="."><plain>Anesthesiol. 2011 61 488 492 10.4097/kjae.2011.61.6.488 <?supplied-pmid 22220226?>22220226 </plain></SENT>
</text></ref><ref id="B24-genes-05-01095"><text><SENT sid="395" pm="."><plain>24. KhojastehA.SartianoG.TapazoglouE.LesterE.GandaraD.BernardS.FinnA. Ondansetron for the prevention of emesis induced by high-dose cisplatin. </plain></SENT>
<SENT sid="396" pm="."><plain>A multi-center dose-response study Cancer 1990 66 1101 1105 10.1002/1097-0142(19900915)66:6&lt;1101::AID-CNCR2820660604&gt;3.0.CO;2-F <?supplied-pmid 2144788?>2144788 </plain></SENT>
</text></ref><ref id="B25-genes-05-01095"><text><SENT sid="397" pm="."><plain>25. JayadevS.BirdT.D. Hereditary ataxias: Overview Genet. </plain></SENT>
<SENT sid="398" pm="."><plain>Med. 2013 15 673 683 10.1038/gim.2013.28 <?supplied-pmid 23538602?>23538602 </plain></SENT>
</text></ref><ref id="B26-genes-05-01095"><text><SENT sid="399" pm="."><plain>26. RequenaT.Espinosa-SanchezJ.M.Lopez-EscamezJ.A. Genetics of dizziness: Cerebellar and vestibular disorders Curr. </plain></SENT>
<SENT sid="400" pm="."><plain>Opin. </plain></SENT>
<SENT sid="401" pm="."><plain>Neurol. 2014 27 98 104 10.1097/WCO.0000000000000053 <?supplied-pmid 24275721?>24275721 </plain></SENT>
</text></ref><ref id="B27-genes-05-01095"><text><SENT sid="402" pm="."><plain>27. RosiniF.FederighiP.PretegianiE.PiuP.LeighR.J.SerraA.FedericoA.RufaA. Ocular-motor profile and effects of memantine in a familial form of adult cerebellar ataxia with slow saccades and square wave saccadic intrusions PLOS ONE 2013 8 e69522 10.1371/journal.pone.0069522 <?supplied-pmid 23894498?>23894498 </plain></SENT>
</text></ref><ref id="B28-genes-05-01095"><text><SENT sid="403" pm="."><plain>28. ShiraiY.AsanoK.TakegoshiY.UchiyamaS.NonobeY.TabataT. A simple machine vision-driven system for measuring optokinetic reflex in small animals J. </plain></SENT>
<SENT sid="404" pm="."><plain>Physiol. </plain></SENT>
<SENT sid="405" pm="."><plain>Sci. 2013 63 395 399 10.1007/s12576-013-0276-5 <?supplied-pmid 23824466?>23824466 </plain></SENT>
</text></ref><ref id="B29-genes-05-01095"><text><SENT sid="406" pm="."><plain>29. ShutohF.OhkiM.KitazawaH.ItoharaS.NagaoS. Memory trace of motor learning shifts transsynaptically from cerebellar cortex to nuclei for consolidation Neuroscience 2006 139 767 777 10.1016/j.neuroscience.2005.12.035 <?supplied-pmid 16458438?>16458438 </plain></SENT>
</text></ref><ref id="B30-genes-05-01095"><text><SENT sid="407" pm="."><plain>30. ZuoJ.de JagerP.L.TakahashiK.A.JiangW.LindenD.J.HeintzN. Neurodegeneration in Lurcher mice caused by mutation in delta2 glutamate receptor gene Nature 1997 388 769 773 10.1038/42009 <?supplied-pmid 9285588?>9285588 </plain></SENT>
</text></ref><ref id="B31-genes-05-01095"><text><SENT sid="408" pm="."><plain>31. WangY.MatsudaS.DrewsV.TorashimaT.MeislerM.H.YuzakiM. A hot spot for hotfoot mutations in the gene encoding the delta2 glutamate receptor Eur. </plain></SENT>
<SENT sid="409" pm="."><plain>J. </plain></SENT>
<SENT sid="410" pm="."><plain>Neurosci. 2003 17 1581 1590 10.1046/j.1460-9568.2003.02595.x <?supplied-pmid 12752376?>12752376 </plain></SENT>
</text></ref><ref id="B32-genes-05-01095"><text><SENT sid="411" pm="."><plain>32. Cull-CandyS.G.WyllieD.J. Glutamate-receptor channels in mammalian glial cells Ann. </plain></SENT>
<SENT sid="412" pm="."><plain>N. </plain></SENT>
<SENT sid="413" pm="."><plain>Y. </plain></SENT>
<SENT sid="414" pm="."><plain>Acad. </plain></SENT>
<SENT sid="415" pm="."><plain>Sci. 1991 633 458 474 10.1111/j.1749-6632.1991.tb15636.x <?supplied-pmid 1686383?>1686383 </plain></SENT>
</text></ref><ref id="B33-genes-05-01095"><text><SENT sid="416" pm="."><plain>33. KatoA.S.KniermanM.D.SiudaE.R.IsaacJ.T.NisenbaumE.S.BredtD.S. Glutamate receptor delta2 associates with metabotropic glutamate receptor 1 (mGluR1), protein kinase Cgamma, and canonical transient receptor potential 3 and regulates mGluR1-mediated synaptic transmission in cerebellar Purkinje neurons J. </plain></SENT>
<SENT sid="417" pm="."><plain>Neurosci. 2012 32 15296 15308 10.1523/JNEUROSCI.0705-12.2012 <?supplied-pmid 23115168?>23115168 </plain></SENT>
</text></ref><ref id="B34-genes-05-01095"><text><SENT sid="418" pm="."><plain>34. HiraiH.LauneyT.MikawaS.TorashimaT.YanagiharaD.KasauraT.MiyamotoA.YuzakiM. New role of delta2-glutamate receptors in AMPA receptor trafficking and cerebellar function Nat. </plain></SENT>
<SENT sid="419" pm="."><plain>Neurosci. 2003 6 869 876 10.1038/nn1086 <?supplied-pmid 12833050?>12833050 </plain></SENT>
</text></ref><ref id="B35-genes-05-01095"><text><SENT sid="420" pm="."><plain>35. YamasakiM.MiyazakiT.AzechiH.AbeM.NatsumeR.HagiwaraT.AibaA.MishinaM.SakimuraK.WatanabeM. Glutamate receptor delta2 is essential for input pathway-dependent regulation of synaptic AMPAR contents in cerebellar Purkinje cells J. </plain></SENT>
<SENT sid="421" pm="."><plain>Neurosci. 2011 31 3362 3374 10.1523/JNEUROSCI.5601-10.2011 <?supplied-pmid 21368048?>21368048 </plain></SENT>
</text></ref><ref id="B36-genes-05-01095"><text><SENT sid="422" pm="."><plain>36. HonoreT.DaviesS.N.DrejerJ.FletcherE.J.JacobsenP.LodgeD.NielsenF.E. Quinoxalinediones: Potent competitive non-NMDA glutamate receptor antagonists Science 1988 241 701 703 10.1126/science.2899909 <?supplied-pmid 2899909?>2899909 </plain></SENT>
</text></ref><ref id="B37-genes-05-01095"><text><SENT sid="423" pm="."><plain>37. KakegawaW.MiyazakiT.KohdaK.MatsudaK.EmiK.MotohashiJ.WatanabeM.YuzakiM. The N-terminal domain of GluD2 (GluRdelta2) recruits presynaptic terminals and regulates synaptogenesis in the cerebellum in vivo J. </plain></SENT>
<SENT sid="424" pm="."><plain>Neurosci. 2009 29 5738 5748 10.1523/JNEUROSCI.6013-08.2009 <?supplied-pmid 19420242?>19420242 </plain></SENT>
</text></ref><ref id="B38-genes-05-01095"><text><SENT sid="425" pm="."><plain>38. RabacchiS.BaillyY.Delhaye-BouchaudN.MarianiJ. Involvement of the N-methyl d-aspartate (NMDA) receptor in synapse elimination during cerebellar development Science 1992 256 1823 1825 10.1126/science.1352066 <?supplied-pmid 1352066?>1352066 </plain></SENT>
</text></ref><ref id="B39-genes-05-01095"><text><SENT sid="426" pm="."><plain>39. GarthwaiteJ.BrodbeltA.R. Synaptic activation of N-methyl-d-aspartate and non-N-methyl-d-aspartate receptors in the mossy fibre pathway in adult and immature rat cerebellar slices Neuroscience 1989 29 401 412 10.1016/0306-4522(89)90067-5 <?supplied-pmid 2566955?>2566955 </plain></SENT>
</text></ref><ref id="B40-genes-05-01095"><text><SENT sid="427" pm="."><plain>40. YuzakiM.ForrestD.VerselisL.M.SunS.C.CurranT.ConnorJ.A. Functional NMDA receptors are transiently active and support the survival of Purkinje cells in culture J. </plain></SENT>
<SENT sid="428" pm="."><plain>Neurosci. 1996 16 4651 4661 <?supplied-pmid 8764653?>8764653 </plain></SENT>
</text></ref><ref id="B41-genes-05-01095"><text><SENT sid="429" pm="."><plain>41. BalazsR.JorgensenO.S.HackN. N-Methyl-d-aspartate promotes the survival of cerebellar granule cells in culture Neuroscience 1988 27 437 451 10.1016/0306-4522(88)90279-5 <?supplied-pmid 2905787?>2905787 </plain></SENT>
</text></ref><ref id="B42-genes-05-01095"><text><SENT sid="430" pm="."><plain>42. OrtegaF.Perez-SenR.MorenteV.DelicadoE.G.Miras-PortugalM.T. P2X7, NMDA and BDNF receptors converge on GSK3 phosphorylation and cooperate to promote survival in cerebellar granule neurons Cell. </plain></SENT>
<SENT sid="431" pm="."><plain>Mol. </plain></SENT>
<SENT sid="432" pm="."><plain>Life Sci. 2010 67 1723 1733 10.1007/s00018-010-0278-x <?supplied-pmid 20146080?>20146080 </plain></SENT>
</text></ref><ref id="B43-genes-05-01095"><text><SENT sid="433" pm="."><plain>43. KadotaniH.HiranoT.MasugiM.NakamuraK.NakaoK.KatsukiM.NakanishiS. Motor discoordination results from combined gene disruption of the NMDA receptor NR2A and NR2C subunits, but not from single disruption of the NR2A or NR2C subunit J. </plain></SENT>
<SENT sid="434" pm="."><plain>Neurosci. 1996 16 7859 7867 <?supplied-pmid 8987814?>8987814 </plain></SENT>
</text></ref><ref id="B44-genes-05-01095"><text><SENT sid="435" pm="."><plain>44. MarmolinoD.MantoM. Past, present and future therapeutics for cerebellar ataxias Curr. </plain></SENT>
<SENT sid="436" pm="."><plain>Neuropharmacol. 2010 8 41 61 10.2174/157015910790909476 <?supplied-pmid 20808545?>20808545 </plain></SENT>
</text></ref><ref id="B45-genes-05-01095"><text><SENT sid="437" pm="."><plain>45. BormannJ. Memantine is a potent blocker of N-methyl-d-aspartate (NMDA) receptor channels Eur. </plain></SENT>
<SENT sid="438" pm="."><plain>J. </plain></SENT>
<SENT sid="439" pm="."><plain>Pharmacol. 1989 166 591 592 10.1016/0014-2999(89)90385-3 <?supplied-pmid 2553441?>2553441 </plain></SENT>
</text></ref><ref id="B46-genes-05-01095"><text><SENT sid="440" pm="."><plain>46. StruppM.BrandtT. Current treatment of vestibular, ocular motor disorders and nystagmus Ther. </plain></SENT>
<SENT sid="441" pm="."><plain>Adv. </plain></SENT>
<SENT sid="442" pm="."><plain>Neurol. </plain></SENT>
<SENT sid="443" pm="."><plain>Disord. 2009 2 223 239 10.1177/1756285609103120 <?supplied-pmid 21179531?>21179531 </plain></SENT>
</text></ref><ref id="B47-genes-05-01095"><text><SENT sid="444" pm="."><plain>47. YoshidaT.KatohA.OhtsukiG.MishinaM.HiranoT. Oscillating Purkinje neuron activity causing involuntary eye movement in a mutant mouse deficient in the glutamate receptor delta2 subunit J. </plain></SENT>
<SENT sid="445" pm="."><plain>Neurosci. 2004 24 2440 2448 10.1523/JNEUROSCI.0783-03.2004 <?supplied-pmid 15014119?>15014119 </plain></SENT>
</text></ref><ref id="B48-genes-05-01095"><text><SENT sid="446" pm="."><plain>48. FaulstichM.van AlphenA.M.LuoC.du LacS.De ZeeuwC.I. Oculomotor plasticity during vestibular compensation does not depend on cerebellar LTD J. </plain></SENT>
<SENT sid="447" pm="."><plain>Neurophysiol. 2006 96 1187 1195 10.1152/jn.00045.2006 <?supplied-pmid 16723418?>16723418 </plain></SENT>
</text></ref><ref id="B49-genes-05-01095"><text><SENT sid="448" pm="."><plain>49. GordonJ.W.UehlingerJ.DayaniN.TalanskyB.E.GordonM.RudomenG.S.NeumannP.E. Analysis of the hotfoot (ho) locus by creation of an insertional mutation in a transgenic mouse Dev. </plain></SENT>
<SENT sid="449" pm="."><plain>Biol. 1990 137 349 358 10.1016/0012-1606(90)90259-L <?supplied-pmid 1689261?>1689261 </plain></SENT>
</text></ref><ref id="B50-genes-05-01095"><text><SENT sid="450" pm="."><plain>50. KashiwabuchiN.IkedaK.ArakiK.HiranoT.ShibukiK.TakayamaC.InoueY.KutsuwadaT.YagiT.KangY. Impairment of motor coordination, Purkinje cell synapse formation, and cerebellar long-term depression in GluR delta 2 mutant mice Cell 1995 81 245 252 10.1016/0092-8674(95)90334-8 <?supplied-pmid 7736576?>7736576 </plain></SENT>
</text></ref><ref id="B51-genes-05-01095"><text><SENT sid="451" pm="."><plain>51. WilsonD.B. Brain abnormalities in the lurcher (Lc) mutant mouse Experientia 1975 31 220 221 10.1007/BF01990715 <?supplied-pmid 1112361?>1112361 </plain></SENT>
</text></ref><ref id="B52-genes-05-01095"><text><SENT sid="452" pm="."><plain>52. NishiyamaJ.MatsudaK.KakegawaW.YamadaN.MotohashiJ.MizushimaN.YuzakiM. Reevaluation of neurodegeneration in lurcher mice: Constitutive ion fluxes cause cell death with, not by, autophagy J. </plain></SENT>
<SENT sid="453" pm="."><plain>Neurosci. 2010 30 2177 2187 10.1523/JNEUROSCI.6030-09.2010 <?supplied-pmid 20147545?>20147545 </plain></SENT>
</text></ref><ref id="B53-genes-05-01095"><text><SENT sid="454" pm="."><plain>53. CendelinJ.TumaJ.KorelusovaI.VozehF. The effect of genetic background on behavioral manifestation of Grid2(Lc) mutation Behav. </plain></SENT>
<SENT sid="455" pm="."><plain>Brain Res. 2014 271 218 227 10.1016/j.bbr.2014.06.023 <?supplied-pmid 24937052?>24937052 </plain></SENT>
</text></ref><ref id="B54-genes-05-01095"><text><SENT sid="456" pm="."><plain>54. SchwartzE.J.RothmanJ.S.DugueG.P.DianaM.RousseauC.SilverR.A.DieudonneS. NMDA receptors with incomplete Mg(2)(+) block enable low-frequency transmission through the cerebellar cortex J. </plain></SENT>
<SENT sid="457" pm="."><plain>Neurosci. 2012 32 6878 6893 10.1523/JNEUROSCI.5736-11.2012 <?supplied-pmid 22593057?>22593057 </plain></SENT>
</text></ref><ref id="B55-genes-05-01095"><text><SENT sid="458" pm="."><plain>55. HeppR.HayY.A.AguadoC.LujanR.DauphinotL.PotierM.C.NomuraS.PoirelO.El MestikawyS.LambolezB. Glutamate receptors of the delta family are widely expressed in the adult brain Brain Struct. </plain></SENT>
<SENT sid="459" pm="."><plain>Funct. 2014 10.1007/s00429-014-0827-4  </plain></SENT>
</text></ref><ref id="B56-genes-05-01095"><text><SENT sid="460" pm="."><plain>56. GlitschM.D. Calcium influx through N-methyl-d-aspartate receptors triggers GABA release at interneuron-Purkinje cell synapse in rat cerebellum Neuroscience 2008 151 403 409 10.1016/j.neuroscience.2007.10.024 <?supplied-pmid 18055124?>18055124 </plain></SENT>
</text></ref><ref id="B57-genes-05-01095"><text><SENT sid="461" pm="."><plain>57. LiuS.J. Biphasic modulation of GABA release from stellate cells by glutamatergic receptor subtypes J. </plain></SENT>
<SENT sid="462" pm="."><plain>Neurophysiol. 2007 98 550 556 10.1152/jn.00352.2007 <?supplied-pmid 17537903?>17537903 </plain></SENT>
</text></ref><ref id="B58-genes-05-01095"><text><SENT sid="463" pm="."><plain>58. DuguidI.C.SmartT.G. Retrograde activation of presynaptic NMDA receptors enhances GABA release at cerebellar interneuron-Purkinje cell synapses Nat. </plain></SENT>
<SENT sid="464" pm="."><plain>Neurosci. 2004 7 525 533 10.1038/nn1227 <?supplied-pmid 15097992?>15097992 </plain></SENT>
</text></ref><ref id="B59-genes-05-01095"><text><SENT sid="465" pm="."><plain>59. HiranoT.WatanabeD.KawaguchiS.Y.PastanI.NakanishiS. Roles of inhibitory interneurons in the cerebellar cortex Ann. </plain></SENT>
<SENT sid="466" pm="."><plain>N. </plain></SENT>
<SENT sid="467" pm="."><plain>Y. </plain></SENT>
<SENT sid="468" pm="."><plain>Acad. </plain></SENT>
<SENT sid="469" pm="."><plain>Sci. 2002 978 405 412 10.1111/j.1749-6632.2002.tb07583.x <?supplied-pmid 12582069?>12582069 </plain></SENT>
</text></ref><ref id="B60-genes-05-01095"><text><SENT sid="470" pm="."><plain>60. WhittinghamD.G. Fertilization of mouse eggs in vitro Nature 1968 220 592 593 10.1038/220592a0 <?supplied-pmid 5686738?>5686738 </plain></SENT>
</text></ref><ref id="B61-genes-05-01095"><text><SENT sid="471" pm="."><plain>61. TabataT.SawadaS.ArakiK.BonoY.FuruyaS.KanoM. A reliable method for culture of dissociated mouse cerebellar cells enriched for Purkinje neurons J. </plain></SENT>
<SENT sid="472" pm="."><plain>Neurosci. </plain></SENT>
<SENT sid="473" pm="."><plain>Methods 2000 104 45 53 10.1016/S0165-0270(00)00323-X <?supplied-pmid 11163410?>11163410 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
